Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
Nizar J. Bahlis, Meletios A. Dimopoulos, Darrell J. White, Lotfi Benboubker, Gordon Cook, Merav Leiba, P. Joy Ho, Kihyun Kim, Naoki Takezako, Philippe Moreau, Jonathan L. Kaufman, Maria Krevvata, Christopher Chiu, Xiang Qin, Linda Okonkwo, Sonali Trivedi, Jon Ukropec, Ming Qi, Jesus San-Miguel
Research output: Contribution to journal › Article › peer-review
197Scopus
citations
Fingerprint
Dive into the research topics of 'Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study'. Together they form a unique fingerprint.